Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA5A | P35218 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL816810 | 0.95 | HTT (0.48) | CYP19A1HTTKMT2AGAAALDH1A1 | |
| SCHEMBL2055461 | 0.88 | ALDH1A1 (0.46) | CYP19A1HTTKMT2AGAAALDH1A1 | |
| SCHEMBL15122462 | 0.86 | KMT2A (0.42) | CYP19A1HTTKMT2AGAAALDH1A1 | |
| SCHEMBL20248063 | 0.86 | KMT2A (0.42) | CYP19A1HTTKMT2AGAAALDH1A1 | |
| SCHEMBL2820707 | 0.86 | ACP1 (0.43) | CYP19A1HTTKMT2AGAAALDH1A1 | |
| SCHEMBL4443081 | 0.85 | CYP19A1 (0.62) | CYP19A1HTTKMT2AGAAALDH1A1 | |
| SCHEMBL23113418 | 0.82 | HTT (0.42) | CYP19A1HTTKMT2AGAAALDH1A1 | |
| SCHEMBL16829550 | 0.82 | PTGS1 (0.46) | HTTKMT2AGAAALDH1A1LMNA | |
| SCHEMBL2310139 | 0.82 | VCAM1 (0.65) | CYP19A1HTTKMT2AGAAALDH1A1 | |
| SCHEMBL17593373 | 0.82 | ALDH1A1 (0.46) | HTTKMT2AGAAALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112745247-A | Novel dye intermediate, novel dye and preparation method thereof | 湖北丽源科技股份有限公司 | 2021-05-04 | — | — | CN | claimed |
| US-12559455-B2 | Compound as a UBR box domain ligand | AUTOTAC INC. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| WO-2023074936-A1 | BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND | 주식회사 오토텍바이오 | 2023-05-04 | — | — | WO | disclosed |
| EP-4144722-A1 | COMPOUND AS UBR BOX DOMAIN LIGAND | Autotac Inc. (KR) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | disclosed |
| CN-112745247-A | Novel dye intermediate, novel dye and preparation method thereof | 湖北丽源科技股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-107556356-B | Method for synthesizing vidarabine | 新乡拓新药业股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| WO-2018104307-A1 | AROMATIC SULFONAMIDE DERIVATIVES AND THEIR USE AS ANATAGON I STS OR NEGATIVE ALLOSTERIC MODULATORS OF P2X4 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-14 | — | — | WO | disclosed |
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-12 | — | — | US | disclosed |
| US-6677349-B1 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| EP-1198233-A4 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1198233-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6331539-B1 | INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-12-18 | — | — | US | disclosed |
| WO-2000076519-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0288824-B1 | AROMATIC DIAMINES CONTAINING SULFONIC ACID ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF POLYURETHANE POLYMERS | BAYER AG (DE) | 1993-08-25 | — | — | EP | disclosed |
| US-4897423-A | Dinitrobenzenesulfonamides | MERCK & CO. INC. (US) | 1990-01-30 | — | — | US | disclosed |
| US-4797427-A | ESTERIFICATION, HYDROGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-01-10 | — | — | US | disclosed |
| US-3996000-A | USING THE EXHAUSTION PROCESS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | CYP19A1 2116/4885HTT 4606/4885KMT2A 443/4885 |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | CYP19A1 2912/4885HTT 258/4885KMT2A 1391/4885 |
| US-12559455-B2 | Compound as a UBR box domain ligand | UBR4, UBTF, UBQLN1 | CYP19A1 4102/4885HTT 286/4885KMT2A 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.